Bethany Sensenig - 19 Feb 2026 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Reporting relationship: Director
Issuer ticker: SUPN
Reported as of: 19 Feb 2026
Net transaction value: -$228,265
SEC form: 4
Accepted by SEC: 23 Feb 2026, 16:39:45 UTC
Prior SEC filing: 20 Feb 2026
Next SEC filing: 17 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Timothy C. Dec, as attorney-in-fact

Key filing fact

Bethany Sensenig filed Form 4 for SUPERNUS PHARMACEUTICALS, INC. (SUPN) on 23 Feb 2026.

Key facts

This page summarizes Bethany Sensenig's Form 4 filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 23 Feb 2026, 16:39.

Change

Previous filing in this sequence was filed on 20 Feb 2026.
Current net transaction value: -$228,265.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001899935 Primary reporting owner

Sensenig Bethany

Relationship: Director
Address: C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE
Signature: /s/ Timothy C. Dec, as attorney-in-fact
Signature date: 23 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SUPN transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +4,475
Change %
Price: $0.000000
Shares after: 4,475
Date: 19 Feb 2026
Ownership: Direct

SUPN transaction

Common Stock

Sale

Transaction value: $61,227
Shares: -1,217
Change %: -27%
Price: $50.31
Shares after: 3,258
Date: 19 Feb 2026
Ownership: Direct
Footnotes: F1, F2

SUPN transaction

Common Stock

Sale

Transaction value: $167,038
Shares: -3,258
Change %: -100%
Price: $51.27
Shares after: 0
Date: 19 Feb 2026
Ownership: Direct
Footnotes: F1, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SUPN transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -4,475
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 19 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,475
Exercise price
Footnotes: F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

Transaction made pursuant to a 10b5-1 trading plan adopted May 15, 2025.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.83 to $50.71. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.98 to $51.56. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Footnote F4

Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

Footnote F5

These restricted stock units were settled in common stock upon vesting, which occurred on February 19, 2026.